Anti-BCMA Antibody Isomerization for Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for BCMA-mediated diseases, such as multiple myeloma, lack effective therapies that specifically target BCMA with high affinity and specificity, leading to inadequate patient responses and progression of the disease.
Innovation Solution
Development of isomerized and oxidized variants of anti-BCMA antibodies with specific heavy and light chain amino acid sequences, including CDR regions, to enhance binding affinity and stability, used in compositions that include antibody-drug conjugates, which are designed to target BCMA with high specificity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody treatments are used for BCMA-mediated diseases, then general B-cell targeting is achieved, but specificity and affinity for BCMA are insufficient
Solution Approach 1:
The patent introduces isomerized variants at specific positions (D103, D105, D107 in CDRH3) to locally modify the antibody structure. This local modification enhances binding affinity and specificity for BCMA without altering the overall antibody framework, resolving the contradiction between general targeting and specific high-affinity binding.
Solution Approach 2:
The patent employs oxidation at specific residues (M34, M36, M38 in CDRH1) to change the chemical parameters of the antibody. These oxidative modifications alter the binding interface properties, enabling higher affinity and specificity for BCMA while maintaining the antibody's overall structure and function.
2Reliability
If antibody variants with modified amino acid sequences are developed, then binding affinity and stability are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent performs isomerization and oxidation modifications during the antibody production process itself, rather than as separate post-production steps. By incorporating these modifications into the manufacturing workflow, the patent enhances stability while avoiding the need for complex additional processing steps that would increase manufacturing complexity.
Solution Approach 2:
The antibody variants are designed to undergo isomerization and oxidation spontaneously under physiological conditions or during standard purification processes. This self-modification capability eliminates the need for complex external modification equipment or procedures, thereby enhancing stability without significantly increasing manufacturing complexity.
Data Source
AI summary
The invention described herein provides compositions comprising anti-BCMA antigen binding proteins and related methods for treating BCMA mediated diseases or disorders.